Evolution of the Average Target: NOV Inc.

Evolution of the Target Price: NOV Inc.

Changes in Analyst Recommendations: NOV Inc.

57f99202af.yXCd0B-kAxIYaZd1r91g_0Vt4LjIft8ucw3wkPRHJ4k.hxeshEXmQUh3Ju836Ks2rHBejoGPR7FYBUWXvbYIRdazNPm8R-toSH8R5A~56d2c2d3cddfa6c256c777560cf57f80
11-20 Zephirin Lowers Price Target on NOV to $16 From $17, Keeps Buy Rating MT
29/10/25 RBC Raises Price Target on NOV to $19 From $17, Keeps Outperform Rating MT
09/10/25 RBC Lowers Price Target on NOV to $17 From $18, Keeps Outperform Rating MT
30/07/25 RBC Cuts Price Target on NOV to $18 From $19, Keeps Outperform Rating MT
28/07/25 NOV's Q2 revenue falls but beats expectations RE
15/05/25 Zephirin Cuts Price Target on NOV to $17 From $19, Keeps Buy Rating MT
30/04/25 RBC Trims Price Target on NOV to $19 From $20, Keeps Outperform Rating MT
24/03/25 Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH… Zonebourse
24/03/25 RBC Upgrades NOV to Outperform From Sector Perform, Maintains $22 Price Target MT
06/02/25 RBC Raises Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
15/01/25 Evercore ISI Downgrades NOV to In Line From Outperform, Adjusts Price Target to $18 From $25 MT
06/01/25 Seaport Downgrades NOV to Neutral From Buy MT
06/01/25 Analyst recommendations: AT&T, Boeing, Nike, T-Mobile, Currys... Zonebourse
19/12/24 Piper Sandler Initiates Coverage on NOV With Neutral Rating, $17 Price Target MT
11/11/24 Citigroup Downgrades NOV to Neutral From Buy, Adjusts Price Target to $18 From $21 MT
28/10/24 Analyst recommendations: Aon, Ciena, Nutanix, Reddit, Resmed... Zonebourse
25/10/24 The Zephirin Group Adjusts Nov's Price Target to $19 from $22; Keeps at Buy MT
25/10/24 Zephirin Group Cuts Price Target on NOV to $19 From $22, Keeps Buy Medium Risk MT
10/10/24 RBC Lowers Price Target on NOV to $21 From $24, Keeps Sector Perform Rating MT
25/09/24 Wells Fargo Downgrades NOV to Underweight From Equalweight, Adjusts PT to $16 From $20 MT
25/09/24 Analyst recommendations: Doordash, Hewlett Packard, Tyson Food, Applovin, Duolingo... Zonebourse
15/07/24 Piper Sandler Adjusts Price Target on NOV to $20 From $22, Maintains Neutral Rating MT
18/04/24 Morgan Stanley Raises Price Target on NOV to $25 From $24 on Removal of 'Saudi Risk Premium,' Keeps Overweight Rating MT
20/02/24 Piper Sandler Adjusts NOV's Price Target to $22 From $25, Keeps Neutral Rating MT
05/02/24 Raymond James Adjusts Price Target on NOV to $25 From $28, Maintains Outperform Rating MT
More recommendations

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-3.74%
+4.64%
+6.35%
-2.79%
-3.19%
+0.24%
-21.16%
+20.85%
+20.51%
+16.13%
Average +3.78%
Weighted average by Cap. +3.26%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
17.23USD
Average target price
17.05USD
Spread / Average Target
-1.04%
High Price Target
22.00USD
Spread / Highest target
+27.68%
Low Price Target
12.00USD
Spread / Lowest Target
-30.35%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Zephirin Group
RBC Capital Markets
Evercore ISI
Seaport Global Securities
Piper Sandler
Citigroup
Zephirin
Wells Fargo Securities
Morgan Stanley
Raymond James
TD Cowen
JPMorgan Chase
Goldman Sachs
BofA Securities
Capital One Securities
Barclays
Cowen
Susquehanna
Benchmark Company
Stifel Nicolaus
UBS
Coker Palmer Institutional
ATB Capital
BMO Capital
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
17.23USD
Average target price
17.05USD
Spread / Average Target
-1.04%
Consensus

Quarterly revenue - Rate of surprise